Brevan Howard Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Brevan Howard Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,516	Closed	-$295K	–	2038
2025 Q3	$295K	Sell	4,516 -28,216	-86%	-$1.38M	﹤0.01%	1574
2025 Q2	$1.29M	Buy	32,732 +9,759	+42%	+$319K	0.01%	941
2025 Q1	$693K	Buy	22,973 +1,607	+8%	+$52.6K	0.01%	621
2024 Q4	$747K	Sell	21,366 -7,113	-25%	-$266K	﹤0.01%	507
2024 Q3	$1.14M	Buy	28,479 +6,632	+30%	+$309K	0.01%	415
2024 Q2	$1.04M	Buy	21,847 +16,923	+344%	+$694K	0.01%	359
2024 Q1	$213K	Buy	+4,924	New	+$235K	﹤0.01%	779

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Brevan Howard Capital Management's IONS Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2025, closing a stake of 4,516 shares — an estimated $295K sold.

Brevan Howard Capital Management first reported a position in IONS in Q1 2024 and held it in 7 quarters. The position peaked at $1.29M in Q2 2025. 491 funds tracked by Wall St. Rank hold IONS as of Q4 2025.

Brevan Howard Capital Management reported no remaining Ionis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Brevan Howard Capital Management sold 4,516 Ionis Pharmaceuticals shares in Q4 2025, an estimated $295K.
Brevan Howard Capital Management first reported a position in Ionis Pharmaceuticals in Q1 2024 and held it in 7 quarters.
Brevan Howard Capital Management's Ionis Pharmaceuticals position peaked at $1.29M in Q2 2025.
491 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.